Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis. (2022)
Attributed to:
Integrative genomic, epigenetic and functional studies in diabetic kidney disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1371/journal.pone.0274136
PubMed Identifier: 36331936
Publication URI: http://europepmc.org/abstract/MED/36331936
Type: Journal Article/Review
Volume: 17
Parent Publication: PloS one
Issue: 11
ISSN: 1932-6203